It has been demonstrated that miR-182, contained within MSC-derived exosomes, can inhibit the expression of vascular endothelial growth factor A (VEGFA) to promote the immune response of T cells, thus slowing RCC progression (Li D. et al., 2021). The gene discussed is VEGFA; the disease is renal cell carcinoma.